ENDRA Life Sciences Inc (NDRA) - Total Assets
Based on the latest financial reports, ENDRA Life Sciences Inc (NDRA) holds total assets worth $7.94 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
ENDRA Life Sciences Inc - Total Assets Trend (2014–2025)
This chart illustrates how ENDRA Life Sciences Inc's total assets have evolved over time, based on quarterly financial data. Also see ENDRA Life Sciences Inc market capitalisation for the company's overall valuation and market capitalisation.
ENDRA Life Sciences Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
ENDRA Life Sciences Inc's total assets of $7.94 Million consist of 25.1% current assets and 74.9% non-current assets. Review NDRA total liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 19.8% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $2.01 Million | 52.2% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2014–2025)
This chart illustrates how ENDRA Life Sciences Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See latest ENDRA Life Sciences Inc stock price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: ENDRA Life Sciences Inc's current assets represent 25.1% of total assets in 2025, a decrease from 57.5% in 2014.
- Cash Position: Cash and equivalents constituted 19.8% of total assets in 2025, down from 22.3% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 52.0% of total assets, an increase from 0.0% in 2014.
- Asset Diversification: The largest asset category is intangible assets at 52.2% of total assets.
ENDRA Life Sciences Inc Competitors by Total Assets
Key competitors of ENDRA Life Sciences Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
GeneDx Holdings Corp.
NASDAQ:WGS
|
USA | $481.49 Million |
|
Shanghai Runda Med Tech Co
SHG:603108
|
China | CN¥13.79 Billion |
|
Shanghai Rendu Biotechnology Co. Ltd. A
SHG:688193
|
China | CN¥984.02 Million |
|
DIVA Laboratories Ltd
TWO:4153
|
Taiwan | NT$1.38 Billion |
|
Genoray Co. Ltd
KQ:122310
|
Korea | ₩131.23 Billion |
|
RHYTHM Biosciences Ltd
AU:RHY
|
Australia | AU$3.10 Million |
|
Check-Cap Ltd
F:7CC
|
Germany | €7.49 Million |
|
Avricore Health Inc
V:AVCR
|
Canada | CA$584.37K |
ENDRA Life Sciences Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 7.10 | 3.21 | 9.18 |
| Quick Ratio | 7.10 | 3.21 | 8.23 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $4.80 Million | $1.28 Million | $12.89 Million |
ENDRA Life Sciences Inc - Advanced Valuation Insights
This section examines the relationship between ENDRA Life Sciences Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.34 |
| Latest Market Cap to Assets Ratio | 2.25 |
| Asset Growth Rate (YoY) | -13.4% |
| Total Assets | $3.85 Million |
| Market Capitalization | $8.68 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values ENDRA Life Sciences Inc's assets at a significant premium (2.25x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: ENDRA Life Sciences Inc's assets decreased by 13.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for ENDRA Life Sciences Inc (2014–2025)
The table below shows the annual total assets of ENDRA Life Sciences Inc from 2014 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $3.85 Million | -13.44% |
| 2024-12-31 | $4.45 Million | -34.08% |
| 2023-12-31 | $6.75 Million | -27.17% |
| 2022-12-31 | $9.27 Million | -27.97% |
| 2021-12-31 | $12.87 Million | +46.89% |
| 2020-12-31 | $8.76 Million | +22.14% |
| 2019-12-31 | $7.18 Million | -0.64% |
| 2018-12-31 | $7.22 Million | +17.95% |
| 2017-12-31 | $6.12 Million | +1147.80% |
| 2016-12-31 | $490.76K | +0.83% |
| 2015-12-31 | $486.72K | -30.76% |
| 2014-12-31 | $702.93K | -- |
About ENDRA Life Sciences Inc
ENDRA Life Sciences Inc. develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is involved in the development of thermo-acoustic enhanced ultrasound technology that uses pulsed energy source such as radio frequency to transmit energy deep into tissue and generate ultrasonic waves to create high-contrast images for use in the treatment of non-alcoholic fa… Read more